XML 67 R52.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Segment Reporting [Abstract] |
Reconciliation of revenue from segments to consolidated | The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.
| Evolent Health Services |  | Clinical Solutions |  | Intersegment Eliminations |  | Subtotal |  | Corporate (1) |  | Consolidated
Revenue |  |  |  |  |  |  |  |  |  |  |
For the Year Ended December 31, 2021 |  |  |  |  |  |  |  |
Transformation services | $ | 11,204 |  |  | $ | — |  |  | $ | — |  |  | $ | 11,204 |  |  | $ | — |  |  | $ | 11,204 |
Platform and operations services | 300,423 |  |  | 598,144 |  |  | (1,814) |  |  | 896,753 |  |  | — |  |  | 896,753 |
Total revenue | $ | 311,627 |  |  | $ | 598,144 |  |  | $ | (1,814) |  |  | $ | 907,957 |  |  | $ | — |  |  | $ | 907,957 |
For the Year Ended December 31, 2020 |  |  |  |  |  |  |  |
Transformation services | $ | 11,990 |  |  | $ | — |  |  | $ | — |  |  | $ | 11,990 |  |  | $ | — |  |  | $ | 11,990 |
Platform and operations services | 373,144 |  |  | 542,279 |  |  | (2,774) |  |  | 912,649 |  |  | — |  |  | 912,649 |
Total revenue | $ | 385,134 |  |  | $ | 542,279 |  |  | $ | (2,774) |  |  | $ | 924,639 |  |  | $ | — |  |  | $ | 924,639 |
For the Year Ended December 31, 2019 |  |  |  |  |  |  |  |
Transformation services | $ | 15,203 |  |  | $ | — |  |  | $ | — |  |  | $ | 15,203 |  |  | $ | — |  |  | $ | 15,203 |
Platform and operations services | 394,328 |  |  | 278,217 |  |  | (626) |  |  | 671,919 |  |  | — |  |  | 671,919 |
Total revenue | $ | 409,531 |  |  | $ | 278,217 |  |  | $ | (626) |  |  | $ | 687,122 |  |  | $ | — |  |  | $ | 687,122 |
| Evolent Health Services |  | Clinical Solutions |  | Subtotal |  | Corporate (1) |  | Segments Total |  |
For the Year Ended December 31, 2021 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 17,063 |  |  | $ | 82,920 |  |  | $ | 99,983 |  |  | $ | (33,666) |  |  | $ | 66,317 |  |  |
For the Year Ended December 31, 2020 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | 57,731 |  |  | $ | 26,864 |  |  | $ | 84,595 |  |  | $ | (36,022) |  |  | $ | 48,573 |  |  |
For the Year Ended December 31, 2019 |  |  |  |  |  |  |  |
Adjusted EBITDA | $ | (561) |  |  | $ | 12,523 |  |  | $ | 11,962 |  |  | $ | (25,793) |  |  | $ | (13,831) |  |  |
———————— (1)Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.
Reconciliation of Adjusted EBITDA to net loss | The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands):
| For the Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | (37,601) |  |  | $ | (334,246) |  |  | $ | (301,971) |
Less: |  |  |  |  |
Interest income | 407 |  |  | 2,633 |  |  | 3,406 |
Interest expense | (25,425) |  |  | (28,325) |  |  | (14,555) |
(Provision) benefit for income taxes | (483) |  |  | 2,368 |  |  | 22,795 |
Depreciation and amortization expenses | (60,037) |  |  | (60,835) |  |  | (60,323) |
Equity method investment impairment | — |  |  | (47,133) |  |  | — |
Gain on transfer of membership | 45,938 |  |  | — |  |  | — |
Loss on repayment of debt, net | (21,343) |  |  | — |  |  | — |
Loss on extinguishment of debt | — |  |  | (4,789) |  |  | — |
Goodwill impairment | — |  |  | (215,100) |  |  | (199,800) |
Gain (loss) from equity method investees | 13,179 |  |  | 10,039 |  |  | (9,465) |
Gain (loss) on disposal of assets | — |  |  | (698) |  |  | 9,600 |
Change in fair value of contingent consideration and indemnification asset | (13,281) |  |  | (3,860) |  |  | 3,997 |
Net loss attributable to non-controlling interests | — |  |  | — |  |  | 3,609 |
Other income (expense), net | (146) |  |  | (118) |  |  | (489) |
Purchase accounting adjustments | — |  |  | — |  |  | (1,915) |
Repositioning costs | (7,318) |  |  | (1,275) |  |  | — |
Stock-based compensation expense | (16,711) |  |  | (14,606) |  |  | (15,618) |
Severance costs | (198) |  |  | (8,986) |  |  | (17,350) |
Amortization of contract cost assets | (476) |  |  | (3,944) |  |  | (2,876) |
Strategy and shareholder advisory expenses | (6,513) |  |  | — |  |  | — |
Acquisition costs | (4,194) |  |  | (2,116) |  |  | (10,769) |
Gain (loss) from discontinued operations (1) | (7,317) |  |  | (6,074) |  |  | 1,613 |
Adjusted EBITDA | $ | 66,317 |  |  | $ | 48,573 |  |  | $ | (13,831) |
———————— (1)Includes $6.8 million gain on disposal of discontinued operations for the year ended December 31, 2021.

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration